Key Takeaways
- Mixed quarter, restructuring underway: Consolidated revenue was marginally lower YoY as CDMO Steriles normalized post-COVID and Generics weakened, but Specialty Pharma improved significantly and CRDMO grew on strong Drug Discovery demand.
- Generics transformation is the big swing factor: A new leadership team is executing a strategic reorganization targeting more than Rs. 100 crore in annualized cost savings, with benefits expected to materialize by next quarter.
- Radiopharma turnaround gaining traction: Volumes reached pre-COVID levels, losses reduced, and the Montreal plant completed a USFDA inspection with zero observations, de-risking a key growth driver.
- Balance sheet strengthened via refinancing: A new $350 million, 5-year facility at less than 2% coupon replaces higher-cost debt, with exceptional foreclosure charges expected to be recovered through interest savings over the new tenor.
- What to watch next quarter: Whether the Roorkee CAPA response clears FDA review by mid-November, the pace of Generics cost savings realization, and any update on Nanjangud reinspection timing.
Generics Restructuring & Remediation
- Strategic reset: The business has been placed under separate leadership (Mr. Jaidev Rajpal) with a mandate for laser-sharp focus on cost optimization, R&D portfolio rebalancing, and reprioritizing branded markets like India for accelerated growth.
- Cost savings identified: More than Rs. 100 crore in annualized cost opportunities have been identified across direct and indirect spend, with execution underway and implementation targeted by Q4 FY23; additional cost-saving opportunities are being scouted across the entire cost base.
- Margin trajectory: EBITDA is expected to improve quarter-on-quarter from here, driven by production ramp-up, selling into non-U.S. markets, and business transformation initiatives. Pricing remains beyond the company's control, so cost reduction is the primary lever.
- Roorkee remediation: The July FDA audit (6 observations) disrupted ongoing remediation activities as equipment suppliers and software partners had to leave the site. Remobilization took time, and remediation completion is now expected by end of October, after which production ramp-up will begin.
- Roorkee CAPA timeline: The CAPA plan has been submitted; FDA generally takes around 90 days to respond, so a response is expected around mid-November.
- Nanjangud overhang: The plant has been under OAI status since its last inspection in 2018. The impact is limited to not being able to position new products into the U.S. market; existing products continue to be exported to the U.S., Europe, Japan, and all other countries. The company has hired internal and external consultants to prepare and is trying to signal readiness to FDA, but the reinspection timeline is unknown.
Yadav: "From here onwards, quarter-on-quarter, our EBITDA will continue to improve."
Specialty Pharmaceuticals: Radiopharma & Allergy
- Radiopharma recovery: Revenue improved significantly YoY and QoQ as volumes reached pre-COVID levels and demand normalized. Losses reduced, reflecting that the turnaround plan is working. Sequential revenue also benefited from customer order rescheduling from Q1 FY23.
- Utilization: Touching more than 95% in all molecules except DTPA, which has not yet come up; the rest of the products have returned to pre-COVID levels.
- Regulatory milestone: The Radiopharma Montreal plant completed a USFDA inspection in early October 2022 with zero observations, de-risking a key manufacturing asset.
- Radiopharmacies: Top line continues to grow via organic growth of existing products and new product launches like PSMA. Operational efficiencies are improving month-on-month and quarter-on-quarter. Management guided to breakeven by end of FY24, though efforts are underway to achieve it much earlier.
- Allergy Immunotherapy: Revenue growth was driven by volume growth, price increases, and geographic expansion.
- MIBG development: Phase II (relapse/refractory) has enrolled 40-45% of ~70 patients; Phase III (first-line with CHOP) has completed 450+ of ~700 patients. The drug is already being used under a special FDA access program in close to 16-18 hospitals.
- MIBG approval timeline: Phase II approval expected in FY25; Phase III approval expected in FY26. Once approved in the U.S., the company will explore EU markets, though nothing has been initiated there yet.
Bhartia: "Now the life of the children improves substantially. They can go back to school, they can go back to their cheerful if this treatment is given. So even if it lasts for 4-5 years, it is very important, the life improvement because when they go through the chemo or any other drug program, their quality of life is very low."
CDMO Sterile Injectables & API
- Sterile Injectables revenue: Normalized YoY due to tapering of one-off COVID-related revenues (Rs. 22 crore in Q2 FY23 vs Rs. 162 crore in Q2 FY22). Sequential improvement was driven by higher volumes.
- Sterile Injectables margin volatility: QoQ variation is structural, driven by regulatory plant shutdowns occurring twice per year (each over 3 weeks). In the shutdown quarter, batches already produced continue to be sold from the queue; in the following quarter, production runs at full capacity but only half the batches are sold, with the balance going into inventory, causing inventory adjustments that swing margins.
- Annualized margin view: On an annualized basis, removing one-offs and COVID-related impact, the CMO business is back to pre-COVID margin levels, which management characterizes as healthy.
- U.S. cost competitiveness: U.S. power costs are better than Europe, and even before the Ukraine crisis, U.S. costs were highly competitive. Management has not seen business moving out of Europe to the U.S. yet, noting that innovator pharma companies prefer sterile injectable fill-finish to be closer to them geographically for quality supervision.
- CDMO API margin improvement: Margin improved sequentially from 4% to 8.5%, driven by plant upgradation and capacity unlock programs that are now completing. From the next quarter, the company expects growth in both volume and profitability, with a target to return to the margin levels the business used to have in past years.
CRDMO & Drug Discovery
- Revenue growth: CRDMO revenue improved both YoY and sequentially, led by strong performance of drug discovery service business. API business also reported double-digit year-on-year growth in revenues, driven by higher volumes.
- Drug Discovery demand: Strong demand from target customers for integrated drug discovery services, functional chemistry, and DMPK, though the market is adopting a more selective approach in launching new projects. Sequential revenue was higher in line with historical Q2 strength.
- Margin pressure: EBITDA margin declined YoY (21.3% vs 26.6%) despite revenue growth.
- Facility expansion: Commissioning and validation of the Greater Noida DMPK in-vitro facility has been completed, enabling comprehensive service capability from the site.
- Inflation pass-through: Costs are rising at a higher pace than normal due to U.S. inflation (employee costs, component costs). Some customer contracts are open for price increases, some have limits, but overall the company is able to more or less pass on the increase. Every year, pricing is indexed to the increase for most customers.
Jubilant Therapeutics Pipeline
- Clinical-stage milestone: Jubilant Therapeutics is now a clinical-stage biotech with higher value-creation opportunities driven by emerging data from first-in-human studies and additional IND filings.
- JBI-802: Phase I/II trial ongoing for advanced solid tumors, targeting subsets of small cell lung cancer, neuroendocrine prostate cancer, and other neuroendocrine tumors with specific genetic signatures. Interim clinical data expected by early next year.
- JBI-778: Received FDA clearance of the IND for an oral, brain-penetrant, selective PRMT5 inhibitor for solid tumors with brain metastases and primary brain tumors.
- Research publication: Cutting-edge findings on a first-in-class PAD4 inhibitor in halting cancer progression and tumor metastasis were published in Cancer Research jointly with The Wistar Institute.
- AACR presentation: Preclinical data on JBI-802 activity in MYC-amplified neuroendocrine tumor models was presented at the AACR Epigenomics conference.
Kazmi: "Jubilant Therapeutics is now a clinical stage biotech with higher value creation opportunities driven by emerging data from first-in-human studies and additional IND filings."
Capital Allocation & Balance Sheet
- Refinancing completed: The previous $200 million bond (due March 2024, 6% coupon) and $150 million term loan (due ~March 2024) were refinanced early with a new 5-year, $350 million term loan facility (July 2022 to July 2027) at a coupon of less than 2%.
- Exceptional cost: Rs. 57 crore in exceptional charges included Rs. 48 crore of foreclosure charges related to bond repayment and write-off of capitalized debt origination costs. Savings from lower interest rates are expected to recover this cost over the new facility's tenor.
- Capex guidance: Expect to incur capex of around Rs. 700-750 crore in FY23, primarily towards expansion in the CMO business and enhancement of Drug Discovery Services capabilities and capacities.
- R&D spend: Product development expenditure of Rs. 250-300 crore expected in FY23.
- Potential demerger: Management has no plans as yet to demerge Pharmova businesses but will evaluate how these businesses are panning out over the next couple of years.
Bhartia: "There is no plans as yet. But I think we'll have to see in the next couple of years how these businesses are panning out."
Guidance & Commitments
| Commitment | Specifics | Timeline |
|---|---|---|
| Generics cost savings | Annualized cost opportunities worth more than Rs. 100 crore to be implemented | By Q4 FY23 |
| Generics EBITDA | Quarter-on-quarter improvement driven by production ramp-up and cost transformation | From Q3 FY23 onwards |
| Roorkee FDA response | CAPA submitted; FDA response expected | Mid-November 2022 |
| CDMO API margin | Return to margin levels the business used to have in past years | From next quarter onwards (no quantified target) |
| Radiopharmacies breakeven | Break even at the network level | By end of FY24 |
| MIBG Phase II approval | U.S. approval for relapse/refractory indication | FY25 |
| MIBG Phase III approval | U.S. approval for first-line indication | FY26 |
| JBI-802 interim data | Interim clinical data readout | Early next year (CY2023) |
| Capex | Rs. 700-750 crore primarily for CMO and Drug Discovery expansion | FY23 |
| Product development spend | Rs. 250-300 crore | FY23 |
Key Metrics
| Metric | Q2 FY23 |
|---|---|
| Consolidated revenue | ₹1,600 crore, vs ₹1,657 crore in Q2 FY22 and ₹1,452 crore in Q1 FY23 |
| Consolidated reported EBITDA | ₹232 crore, vs ₹344 crore in Q2 FY22 and ₹204 crore in Q1 FY23 |
| Consolidated PAT | ₹5 crore, vs ₹143 crore in Q2 FY22 and ₹47 crore in Q1 FY23 |
| Consolidated normalized PAT | ₹62 crore, vs ₹143 crore in Q2 FY22 and ₹47 crore in Q1 FY23 |
| EPS | ₹0.34 per share, vs ₹8.97 in Q2 FY22 and ₹2.96 in Q1 FY23 |
| Normalized EPS | ₹3.88 per share |
| Specialty Pharmaceuticals revenue | ₹814 crore, up from ₹651 crore in Q2 FY22 and ₹722 crore in Q1 FY23 |
| Specialty Pharmaceuticals EBITDA margin | 24.4%, vs 19.9% in Q2 FY22 and 16.2% in Q1 FY23 |
| CDMO Sterile Injectable revenue | ₹299 crore, vs ₹409 crore in Q2 FY22 and ₹263 crore in Q1 FY23 |
| CDMO Sterile Injectable COVID-related deals | ~₹22 crore, vs ~₹162 crore in Q2 FY22 and ~₹70 crore in Q1 FY23 |
| Generics revenue | ₹161 crore, vs ₹333 crore in Q2 FY22 and ₹178 crore in Q1 FY23 |
| CRDMO revenue | ₹320 crore, vs ₹258 crore in Q2 FY22 and ₹280 crore in Q1 FY23 |
| CRDMO EBITDA margin | 21.3%, vs 26.6% in Q2 FY22 and 16.3% in Q1 FY23 |
| Net debt (constant currency) | ₹2,204 crore, vs ₹1,951 crore as on June 30, 2022 |
| Exceptional cost (foreclosure charges) | ₹57 crore, including ₹48 crore of bond foreclosure charges and write-off of debt origination costs |
| Generics cost optimization identified | >₹100 crore annualized, to be implemented by Q4 FY23 |
| Radiopharma utilization | >95% in all molecules except DTPA |
| MIBG Phase II trial enrollment | 40% to 45% of ~70 patients enrolled and dosed |
| MIBG Phase III trial enrollment | >450 of ~700 patients dosed |
| Refinanced debt coupon | <2%, 5-year $350 million term loan replacing $200 million bonds at 6% and $150 million term loan |
| FY23 capex guidance | ₹700-750 crore, primarily for CMO expansion and Drug Discovery Services |
| FY23 product development expenditure guidance | ₹250-300 crore |